The HDAC inhibitors Vorinostat, Romidepsin and Belinostat have been approved by the FDA for the treatment of T cell lymphoma (Zhang et al. 2019). This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.